Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma

2.1 Carfilzomib (Kyprolis, Amgen) 'in combination with daratumumab and dexamethasone, with lenalidomide and dexamethasone, or with dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy'.

2.2 The dosage schedule is available in the summary of product characteristics.

2.3 The list price of carfilzomib is £1,056 for a 60‑mg vial (excluding VAT; BNF online, accessed January 2021). Multiple courses of treatment may be used in combination with lenalidomide and dexamethasone. The company has a commercial arrangement. This makes carfilzomib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

2.4 The list price of lenalidomide per 21‑capsule pack varies according to capsule size: £3,426.00 (2.5 mg), £3,570.00 (5 mg), £3,675.00 (7.5 mg), £3,780.00 (10 mg), £3,969.00 (15 mg), £4,168.50 (20 mg) and £4,368.00 (25 mg) (excluding VAT; BNF online, accessed January 2021). The company has a commercial arrangement. This makes lenalidomide available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.